- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07944118
Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes
Investigation of the Effect of Fasting Duration and Temporary Withholding of Subcutaneous Administration of Zenagamtide on Retained Gastric Contents in Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The purpose of this clinical study is to find out how the duration of fasting (not eating or drinking, except for water) and pausing of treatment with zenagamtide medication affect the amount of food and liquid left in the stomach of people using zenagamtide.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- Altasciences Clinical LA, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female (sex assigned at birth, inclusive of all gender identities).
- Age 18 and older at the time of signing the informed consent.
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.
For participants with type 2 diabetes (T2D)
- Diagnosed with type 2 diabetes (T2D) more than (>) 180 days before screening.
- No treatment with oral anti-diabetic drugs except metformin. Treatment with metformin should be stable (dose and dosing frequency) for at least 90 days before screening.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders as judged by the investigator.
- Diagnosed with or suspected to suffer from gastroparesis, hiatal hernia or severe gastro-oesophageal reflux diseases with daily symptoms and/or when in supine position.
- Use of other medications known to affect the motility of the stomach.
- Inability to lie in the right lateral decubitus position for gastric ultrasonography.
For participants without T2D - Glycated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) [48 millimoles per mole (mmol/mol)] at screening.
For participants with T2D
- HbA1c ≥ 10.5 % (91 mmol/mol) at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Zenagamtide
Participants will receive zenagamtide once weekly subcutaneously (s.c.). |
Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors in one of the body parts: thigh, abdomen or upper arm. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Gastric volume after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as milliliter per kilogram (mL/kg) |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Gastric volume after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Gastric volume after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
|
|
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
|
Gastric volume after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as mL/kg |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
|
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Time Frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Measured as count of participants |
6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9490-8698
- U1111-1336-6870 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.